Notice: This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrends LOGC vs. BYON, PIK, ETD, HLF, HZO, PTLO, SPTN, MYTE, EXTO, and BBWShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include Beyond (BYON), Kidpik (PIK), Ethan Allen Interiors (ETD), Herbalife (HLF), MarineMax (HZO), Portillo's (PTLO), SpartanNash (SPTN), MYT Netherlands Parent B.V. (MYTE), Almacenes Éxito (EXTO), and Build-A-Bear Workshop (BBW). These companies are all part of the "retail/wholesale" sector. LogicBio Therapeutics vs. Beyond Kidpik Ethan Allen Interiors Herbalife MarineMax Portillo's SpartanNash MYT Netherlands Parent B.V. Almacenes Éxito Build-A-Bear Workshop Beyond (NYSE:BYON) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap retail/wholesale companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability. Does the media prefer BYON or LOGC? In the previous week, Beyond had 7 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 7 mentions for Beyond and 0 mentions for LogicBio Therapeutics. Beyond's average media sentiment score of 0.04 beat LogicBio Therapeutics' score of 0.00 indicating that Beyond is being referred to more favorably in the media. Company Overall Sentiment Beyond Neutral LogicBio Therapeutics Neutral Which has stronger earnings & valuation, BYON or LOGC? Beyond has higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than Beyond, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyond$1.48B0.16-$307.84M-$7.39-0.69LogicBio Therapeutics$287M0.62-$317M-$5.79-1.16 Does the MarketBeat Community believe in BYON or LOGC? LogicBio Therapeutics received 72 more outperform votes than Beyond when rated by MarketBeat users. Likewise, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 52.78% of users gave Beyond an outperform vote. CompanyUnderperformOutperformBeyondOutperform Votes1952.78% Underperform Votes1747.22% LogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% Do institutionals & insiders have more ownership in BYON or LOGC? 76.3% of Beyond shares are owned by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are owned by institutional investors. 1.2% of Beyond shares are owned by company insiders. Comparatively, 8.1% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, BYON or LOGC? Beyond has a beta of 3.7, meaning that its share price is 270% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Do analysts rate BYON or LOGC? Beyond currently has a consensus target price of $16.50, suggesting a potential upside of 224.17%. Given Beyond's stronger consensus rating and higher possible upside, equities research analysts plainly believe Beyond is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beyond 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BYON or LOGC more profitable? Beyond has a net margin of -22.82% compared to LogicBio Therapeutics' net margin of -141.03%. Beyond's return on equity of -69.32% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beyond-22.82% -69.32% -35.45% LogicBio Therapeutics -141.03%-81.98%-52.13% SummaryBeyond beats LogicBio Therapeutics on 13 of the 18 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$176.86M$601.15M$24.51B$9.08BDividend YieldN/AN/A167.12%4.23%P/E Ratio-1.16N/A109.0017.18Price / Sales0.620.663.13116.99Price / CashN/AN/A21.7837.86Price / Book0.751.275.424.78Net Income-$317M-$26.95M$676.04M$225.60M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics0.7546 of 5 stars$6.73+1.5%N/AN/A$176.86M$287M-1.1662Gap DownBYONBeyond3.7859 of 5 stars$5.01-4.6%$16.50+229.3%-79.7%$230.71M$1.56B0.001,050Analyst DowngradeNews CoveragePIKKidpikN/A$2.01-2.9%N/A-3.4%$3.92M$14.24M0.0030Gap UpETDEthan Allen Interiors3.7614 of 5 stars$29.68-1.6%$32.00+7.8%-9.9%$754.76M$636.67M12.213,404Positive NewsHLFHerbalife4.6857 of 5 stars$7.23-3.3%$9.90+36.9%-56.6%$728.73M$5.00B8.669,200HZOMarineMax4.4125 of 5 stars$32.12+4.7%$41.83+30.2%-22.1%$725.75M$2.43B19.454,050Analyst DowngradeGap UpPTLOPortillo's3.089 of 5 stars$9.12-4.0%$14.00+53.5%-45.1%$676.89M$679.91M22.698,180SPTNSpartanNash3.8558 of 5 stars$19.50-0.6%$20.00+2.6%-16.2%$658.32M$9.73B14.6917,000MYTEMYT Netherlands Parent B.V.0.4872 of 5 stars$7.69+7.9%$4.88-36.6%+125.1%$655.70M$855.09M-15.841,817Positive NewsHigh Trading VolumeEXTOAlmacenes ÉxitoN/A$3.96-2.5%N/A-45.9%$642.43M$4.90B11.6043,134News CoverageGap DownBBWBuild-A-Bear Workshop3.3392 of 5 stars$43.68+6.5%$52.50+20.2%+90.0%$590.47M$495.24M10.914,550Analyst UpgradeNews CoverageGap Down Related Companies and Tools Related Companies Beyond Alternatives Kidpik Alternatives Ethan Allen Interiors Alternatives Herbalife Alternatives MarineMax Alternatives Portillo's Alternatives SpartanNash Alternatives MYT Netherlands Parent B.V. Alternatives Almacenes Éxito Alternatives Build-A-Bear Workshop Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LOGC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LOGC Stock Alerts